Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)163.56
  • Today's Change0.195 / 0.12%
  • Shares traded1.71m
  • 1 Year change51.03%
  • Beta0.2616
Data delayed at least 15 minutes, as of Jul 13 2020 19:46 BST.
More ▼

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

  • Revenue in USD (TTM)23.09bn
  • Net income in USD5.53bn
  • Incorporated1901
  • Employees33.63k
  • Location
    Eli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LLY:NYQ since
announced
Transaction
value
Dermira IncDeal completed10 Jan 202010 Jan 2020Deal completed20.33%1.07bn
Data delayed at least 15 minutes, as of Jul 13 2020 19:46 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gilead Sciences, Inc.22.72bn4.96bn95.73bn11.80k19.624.3415.134.213.893.8917.8617.600.37064.986.321,925,085.008.0518.079.4821.8879.3783.4221.7239.312.9221.200.520725.341.46-2.04-1.34-14.958.17--
Bristol-Myers Squibb Co31.01bn954.00m129.95bn30.00k70.992.6025.594.190.8090.80916.6522.060.37794.645.261,033,533.001.198.561.4411.2169.1672.593.1617.511.515.320.483172.4515.8910.49-30.8911.419.712.64
Amgen, Inc.23.97bn7.68bn146.50bn23.40k19.5115.4414.256.1112.7712.7739.8916.130.38141.445.461,024,188.0012.2110.8315.1812.6779.9181.7532.0234.011.2813.400.770541.54-1.623.09-6.588.74-9.2318.91
Eli Lilly And Co23.09bn5.53bn156.25bn33.63k27.0850.7523.386.776.036.0325.163.220.58371.564.49686,605.2013.998.7620.1012.2879.2276.6223.9716.770.86372.760.843564.423.842.6239.4514.17-2.875.65
AbbVie Inc34.06bn8.39bn170.65bn30.00k17.13--16.245.015.655.6522.94-5.020.46034.415.661,135,233.0011.409.9014.3512.7277.0677.1424.7721.343.039.091.1279.291.5710.7636.5534.62-2.0420.86
Pfizer Inc.50.66bn15.47bn187.92bn88.30k12.362.898.873.712.742.808.9911.710.31491.215.20573,725.909.636.2712.027.6880.3779.4030.5920.230.7765--0.444573.76-3.540.850354.1511.9110.386.72
Merck & Co., Inc.48.08bn10.20bn193.67bn71.00k19.307.3914.084.033.973.9618.7310.380.57492.326.09677,211.3012.186.5016.298.2772.1767.9321.1814.300.865728.970.515688.9810.752.0953.02-3.5321.405.13
Data as of Jul 13 2020. Currency figures normalised to Eli Lilly and Co's reporting currency: US Dollar USD

Institutional shareholders

33.38%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202068.46m7.15%
BlackRock Fund Advisorsas of 31 Mar 202044.51m4.65%
PRIMECAP Management Co.as of 31 Mar 202041.94m4.38%
SSgA Funds Management, Inc.as of 31 Mar 202037.05m3.87%
Wellington Management Co. LLPas of 31 Mar 202036.02m3.76%
Fidelity Management & Research Co. LLCas of 31 Mar 202026.50m2.77%
Capital Research & Management Co. (International Investors)as of 31 Mar 202022.78m2.38%
State Farm Investment Management Corp.as of 31 Mar 202018.62m1.95%
Geode Capital Management LLCas of 31 Mar 202012.65m1.32%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202010.92m1.14%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.